Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice

Madsen, Mette Simone Aae; Grønlund, Rikke Veggerby; Eid, John; Christensen-Dalsgaard, Mikkel; Sommer, Morten Otto Alexander; Rigbolt, Kristoffer; Madsen, Martin Rønn; Jelsing, Jacob; Vrang, Niels; Hansen, Henrik H.

Total number of authors: 11

Published in:
Biomedicine and Pharmacotherapy

Link to article, DOI:

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

Citation (APA):
Original article

Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice

Mette Simone Aae Madsen a, b, *, Rikke Vegerby Grønlund a, John Eid c, Mikkel Christensen-Dalsgaard a, Morten Sommer b, Kristoffer Rigbolt c, Martin Rønn Madsen a, Jacob Jelsing a, Niels Vrang a, Henrik H. Hansen a, Martin Mikkelsen a

a Gubra, Hørsholm, Denmark
b Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs. Lyngby, Denmark
b Pendulum, San Francisco, CA, USA

ARTICLE INFO

Keywords:
- Peroxisome proliferator-activated receptor-γ
- Diabetes
- Mouse model
- Gut microbiome
- Gut transcriptome
- Gut segment

ABSTRACT

The gut microbiota has been implicated in the therapeutic effects of antidiabetics. It is unclear if antidiabetics directly influence gut microbiome-host interaction. Oral peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, such as rosiglitazone, are potent insulin sensitizers used in the treatment of type 2 diabetes (T2D). PPAR-γ is abundantly expressed in the intestine, making it possible that PPAR-γ agonists directly influence gut microbiome-host homeostasis. The presented study therefore aimed to characterize local gut microbiome and intestinal transcriptome responses in diabetic db/db mice following rosiglitazone treatment. Diabetic B6.BKS(D)-Lep db/db (db/db) mice (8 weeks of age) received oral dosing once daily with vehicle (n = 12) or rosiglitazone (3 mg/kg, n = 12) for 8 weeks. Gut segments (duodenum, jejunum, ileum, caecum, and colon) were sampled for paired analysis of gut microbiota and host transcriptome signatures using full-length bacterial 16S rRNA sequencing and RNA sequencing (n = 5–6 per group). Treatment with rosiglitazone improved glucose homeostasis without influencing local gut microbiome composition in db/db mice. In contrast, rosiglitazone promoted marked changes in ileal and colonic gene expression signatures associated with peroxisomal and mitochondrial lipid metabolism, carbohydrate utilization and immune regulation. In conclusion, rosiglitazone treatment markedly affected transcriptional markers of intestinal lipid metabolism and immune regulation but had no effect on the gut microbiome in diabetic db/db mice.

1. Introduction

There is an increasing focus on the potential contributory mechanistic role of the gut microbiota in the metabolic effects of glucoregulatory and weight loss promoting drugs [1–4]. Pharmacological treatment of T2D focus on re-establishing glycaemic control using glucose-lowering and insulin sensitizing drugs such as metformin, DPP-4 inhibitors, GLP-1 receptor agonists and selective peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, also termed thiazolidinediones (TZDs) [5,6].

PPAR-γ is a ligand-activated transcription factor belonging to a family of nuclear hormone receptors for which lipids and their metabolic products are endogenous ligands [7–10]. By forming a heterodimer with retinoid X receptors (RXR), nuclear PPAR-γ regulates the expression of a large variety of genes involved in lipid and carbohydrate metabolism [9, 11]. Notably, PPAR-γ activation upregulates genes that stimulate insulin signaling as well as transport and disposal of fatty acids [8]. In addition to prominent effects of PPAR-γ on glucose and lipid metabolism in adipose, hepatic and muscle tissue [8,9], the intestine express PPAR-γ and gut microbiota-host interaction through PPAR-γ signalling has been proposed to play a role in gut metabolism and homeostasis [12–14]. For example, fermentation end products of dietary fibers by the intestinal microbiota can activate PPAR-γ signaling in intestinal endothelial cells, which links gut microbiota-host crosstalk to intestinal PPAR-γ signaling [12,15–18]. In addition to a prominent role in nutrient metabolism, PPAR-γ influences intestinal immune responses by regulating the retinoid X receptors (RXR), nuclear PPAR-γ regulates the expression of a large variety of genes involved in lipid and carbohydrate metabolism [9, 11]. Notably, PPAR-γ activation upregulates genes that stimulate insulin signaling as well as transport and disposal of fatty acids [8]. In addition to prominent effects of PPAR-γ on glucose and lipid metabolism in adipose, hepatic and muscle tissue [8,9], the intestine express PPAR-γ and gut microbiota-host interaction through PPAR-γ signalling has been proposed to play a role in gut metabolism and homeostasis [12–14]. For example, fermentation end products of dietary fibers by the intestinal microbiota can activate PPAR-γ signaling in intestinal endothelial cells, which links gut microbiota-host crosstalk to intestinal PPAR-γ signaling [12,15–18]. In addition to a prominent role in nutrient metabolism, PPAR-γ influences intestinal immune responses by regulating the
recruitment and activity of various immune cell populations of the innate and adaptive immune system [19]. These effects are considered to limit intestinal pro-inflammatory responses which may contribute to maintain intestinal barrier integrity by sustaining tolerance to commensals [18,20,21]. Accordingly, PPAR-γ agonists reduce the release of pro-inflammatory cytokines and suppress NF-κB signalling pathways in gut epithelial cells [22–25]. Also, anti-inflammatory effects of PPAR-γ agonists have been demonstrated in animal models of gut inflammatory diseases [26,27].

There is an increasing appreciation that obesity and T2D is associated with altered composition and activity of gut bacteria involved in nutrient metabolism, dietary energy harvest and host immune responses [19,21,28,29]. PPAR-γ is abundantly expressed in the intestine, making it possible that oral TZDs modulate gut microbiome-host dynamics which may potentially contribute to the therapeutic effects of this drug class. To investigate a potential gut effect of TZDs in the context of diabetes, we therefore characterized local gut microbiome gene and host transcriptional responses to long-term treatment with rosiglitazone, a standard T2D [5,6], in diabetic db/db mice.

2. Materials and methods

2.1. Animals

Eight-weeks-old male B6.BKS(D)-Lepob/J (db/db) mice (Janvier Labs, Saint Berthevin, Cedex, France) were housed in a controlled environment (12 h light/dark cycle, lights on/off at 3AM/3 PM; 22 ± 1 °C; 50 ± 10 % relative humidity). All animals were pair-housed, each identified by an implantable microchip (PetID Microchip, E-vet, Haderslev, Denmark). Mice were fed chow (Purina 5008, 3.31 kcal/g, LabDiet, St. Louis, MO) and received domestic quality tap water ad libitum. All animal experiments were approved by the Danish Committee for Animal Research using internationally accepted principles for the use of laboratory animals (license no. 2013-15-2934–00784).

2.2. Drug treatment

Rosiglitazone was acquired from Sigma-Aldrich (St. Louis, MO). Vehicle was phosphate-buffered saline with 0.1 % Tween-80 (pH 7.4). Animals were randomized to treatment (n = 12 per group) according to body weight, 4 h fasted blood glucose and HbA1c levels. Animals were perorally administered vehicle (5 mL/kg) or rosiglitazone (3.0 mg/kg) once daily for a total of 55 days. Body weight and food intake were measured daily during the treatment period.

2.3. Oral glucose tolerance test

Oral glucose tolerance tests (OGTT) were performed on treatment days 28 and 49. Animals were fasted for 4 h prior to the OGTT. Vehicle and rosiglitazone were administered after the OGTT. At time t = 0, a bolus of glucose (2 g/kg, 10 mL/kg, Fresenius Kabi, Uppsala, Sweden) was administered by oral gavage. Tail vein blood samples were collected in 10 μL heparinized capillary tubes at t = –60, 0, 15, 30, 60, 120 and 180 min, and immediately suspended in glucose/lactate solution buffer (0.5 mL, EKF-diagnostics, Cardiff, UK). Blood glucose concentrations were measured using a BIOSEN C-Line glucose meter (EKF-diagnostics, Barleben, Germany) according to the manufacturer’s instructions.

2.4. Plasma biochemistry

Blood glucose levels were measured once weekly in tail blood samples from 4 h fasted mice. Animals were terminated by cardiac puncture under isoflurane anesthesia. Cardiac blood samples were collected in heparinized tubes and centrifugated (1500 × g, 10 min, 4 °C) for collection of plasma. Terminal plasma samples were assayed for insulin and HbA1c. Insulin was measured in duplicates using an AlphaLisa kit (Perkin Elmer, Skovlunde, Denmark), according to the manufacturer’s instructions. HbA1c was measured using commercial kits (Roche Diagnostics, Hvidovre, Denmark) on the Cobas c 501 autoanalyzer according to the manufacturer’s instructions.

2.5. Simultaneous extraction of bacterial DNA and gut RNA

Vehicle-dosed (n = 5) and rosiglitazone-treated (n = 6) mice were characterised for gut microbiome and transcriptome signatures. Segments (1 cm) from five individual gut regions (duodenum, jejunum, ileum, caecum and proximal colon) were dissected, snap frozen and stored at –80 °C until further processing (Figs. 1.2 A). Simultaneous isolation of DNA and RNA from each individual gut sample was performed using ZymoBIOMICS DNA/RNA Miniprep Kit (ZYMO Research, Irvine, CA) to reduce bias associated with unequal lysis efficiency. In brief, with a FastPrep®–24 system samples were homogenized (1 min shaking every 2nd min, 5 cycles) in DNA/RNA Shield. The lysate was subsequently split and loaded onto two separate columns for DNA and RNA extraction. An in-column DNase I treatment step of RNA samples was included. A positive mock sample (ZYMOBIOMICS Microbial Community Standard II (Log Distribution), ZYMO Research, Irvine, CA) served for DNA extraction efficiency.

2.6. Full-length 16S rRNA amplicon sequencing

500 ng of purified bacterial DNA from each sample served as template and was amplified by PCR (95 °C for 1 min, 29 × (95 °C for 20 s, 55 °C for 30 s, 65 °C for 2 min), 65 °C for 5 min) with 12 barcoding primers (16S Barcoding Kit, SQK-RAB204, Oxford Nanopore Technologies, Oxford, UK) targeting the ~1500 bp 16S rDNA gene, which is specific for bacteria. 16S DNA libraries were verified with both Qubit 4 Fluorometer (Thermo Fisher Scientific, Waltham, MA) and High Sensitivity DNA chips on a 2100 Bioanalyzer Instrument (Agilent Technologies, Santa Clara, CA). Four samples were excluded due to low bacterial content or sample contamination. Finalized 16S DNA libraries were pooled and prepared with a Flow Cell Priming Kit (EXP-FLP001, Oxford Nanopore Technologies) and loaded on a Flow Cell (FLO-MIN106D, Oxford Nanopore Technologies) onto a MinION Nanopore sequencer (Oxford Nanopore Technologies). Library pools had concentrations between 25.6–73.1 fmol. Sequencing runs ran for 6 h using the MinION control software MinKNOW (MinION Release 19.06.8). A positive DNA mock sample (ZYMOBIOMICS Microbial Community DNA Standard II (Log Distribution)) was included in each round of library preparation to control for library size and PCR replicates.

2.7. Microbiome analysis

Nanopore sequencing raw FAST5 files were basecalled and demultiplexed by ONT Guppy basecalling software (v3.2.2) with default settings [30]. Samples with less than 25,000 reads were excluded, resulting in 46 samples for analysis. Passed reads were analysed downstream with Minimap2 (v2.17) and aligned to NCBI 16S rRNA gene database (version from 2019-09-05) identifying bacteria at genus level [31–33]. Single counts were removed, and samples were rarefied to an even depth with Phyloseq (v1.28.0) in R studio (R v3.6.0) [34]. Microbiome diversity and richness analysis was conducted as described previously [35,36].

2.8. Gene expression analysis using RNAseq

A total of 500 ng purified RNA from each sample was used to generate cDNA libraries using the NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA). Oligo dT-based mRNA isolation was used to specifically enrich for eukaryotic mRNAs. cDNA libraries were evaluated with Nanodrop (Thermo Fisher Scientific, Waltham, MA) and hereafter sequenced (75 base-pair, single-reads) on a NextSeq 500 using NextSeq 500/550 High Output Kit V2
Fig. 1. Rosiglitazone improves metabolic parameters in db/db mice. (A) Oral glucose tolerance test (OGTT) on treatment day 28 and glucose area-under-the-curve calculated from the OGTT glucose excursion curve; (B) Oral glucose tolerance test (OGTT) on treatment day 49 and glucose area-under-the-curve calculated from the OGTT glucose excursion curve; (C) Weekly morning blood glucose concentrations (mmol/L), measured after four hours fasting; (D) Plasma HbA1c levels (%) at day 55; (E) Absolute body weight (g); (F) Daily food intake (g). **p < 0.01, ***p < 0.001 versus vehicle controls.
Fig. 2. Gut microbiome analysis of db/db mice by full-length 16S rRNA gene sequencing. (A) Outline of the murine gastrointestinal tract with delineation of gut segments sampled for analysis. (B) Principal Coordinate Analysis (PCoA) calculated by Bray-Curtis dissimilarity between samples based on rarefied data. Gut sections are coloured, and treatment groups shaped. Group means are indicated by a large point. Taxonomic summary of top 10 (C) families and (D) genera across all samples according to highest abundance and represented by mean values per group and gut section. Microbial alpha-diversity analysis at genus level illustrated by (E) richness and (F) Shannon diversity index.
3. Results

3.1. Rosiglitazone improves insulin sensitivity in diabetic db/db mice

The two groups of db/db mice showed similar baseline body weight (vehicle, 40.8 ± 0.8 g; rosiglitazone 40.7 ± 0.2 g, p = 0.876), fastest blood glucose concentrations (vehicle, 10.7 ± 0.8 mmol/L; rosiglitazone 10.7 ± 0.8 mmol/L, p = 0.983) and HbA1c levels (vehicle, 4.7 ± 0.2 %; rosiglitazone 4.5 ± 0.1 %, p = 0.334). Plasma insulin levels remained stable throughout the entire dosing period in vehicle controls: baseline: 6999 ± 327 pg/mL; termination: 7628 ± 1076 pg/mL, p = 0.570) and rosiglitazone-treated db/db mice (baseline: 5988 ± 295 pg/mL; termination: 5718 ± 841 pg/mL, p = 0.741). Rosiglitazone significantly improved glucose excursions in two successive OGTTs performed on treatment day 28 (p < 0.001, Fig. 1 A) and 49 (p < 0.001, Fig. 1 B). Rosiglitazone also improved weekly fasting blood glucose levels and terminal HbA1c levels (p < 0.001, Fig. 1C, D). Compared to vehicle dosing, rosiglitazone transiently increased daily body weight gain in db/db mice (from treatment day 15–26, p < 0.05) without significantly affecting weekly food intake (Fig. 1E, F).

3.2. Rosiglitazone does not influence local gut microbiome composition in diabetic db/db mice

Gut bacterial composition and host gene expression was analyzed in five individual gut segments of the db/db mouse (Fig. 2A). Dual bacterial DNA and host mRNA extraction was applied for direct comparison of gut microbial composition and host gene expression profiles. Rosiglitazone showed no significant effect on gut bacterial composition in db/db mice. A Principal Coordinate Analysis (PCoA) demonstrated that samples of the small intestine clustered closely together, i.e. displaying relatively low between-community diversity (beta-diversity) (Fig. 2B). Samples of the large intestine clustered less on PC2, signifying higher bacterial diversity between these samples. Thus, gut bacterial signatures were homogenous within individual gut segments of vehicle dosed db/db mice. Samples from the small intestine (duodenum, jejunum, and ileum) displayed more similar gut bacterial family and genera composition compared to samples from the large intestine (caecum and colon) (Fig. 2C, D). As determined by relative abundance at bacterial family level, Lactobacillaceae and Lachnospiraceae were predominant in the small and large intestine, respectively (Fig. 2C). While Lactobacillus was the most relatively abundant genus (~75 % of all genera) in the small intestine, the large intestine was characterized by more diverse genus composition predominantly composed by Kineothrix, Lactobacillus and Bliaatia (Fig. 2D). The large intestine showed more diverse bacterial composition as illustrated by increased sample richness and Shannon diversity (alpha-diversity) as compared to the small intestine (Fig. 2E, F).

3.3. Rosiglitazone displays gut segment-specific effects on gene expression

A global gene expression analysis in rosiglitazone-treated db/db mice indicated gut segment-specific changes in gene expression patterns compared to vehicle controls. Gene expression was largely unaffected in the duodenum of rosiglitazone-treated db/db mice (n = 3 differentially expressed genes (DEGs), p < 0.05), jejenum (n = 1 DEG, p < 0.05) and caecum (n = 20 DEGs, p < 0.05) (Fig. 3A). In contrast, rosiglitazone-treated db/db mice showed substantial changes in gene expression signatures in the ileum (n = 744 DEGs, p < 0.05) and colon (n = 833 DEGs, p < 0.05) with only a minor overlap between DEGs in the two gut segments (Fig. 3B). The RNA sequencing analysis indicated highly different transcriptome profiles across the five gut segments analyzed as illustrated by a principal component analysis (PCA) plot (Fig. 3C). PPAR-γ gene expression was detected throughout the gastrointestinal tract in vehicle-dosed db/db mice, showing highest expression in the colon (RPKM values ± SEM; duodenum 15.4 ± 8.7; jejenum 3.5 ± 0.6; ileum 6.7 ± 0.7; caecum 27.8 ± 7.7; colon 50.4 ± 3.3). Rosiglitazone treatment did not alter expression of PPAR-γ (RPKM values ± SEM; duodenum 12.6 ± 2.4; jejenum 3.4 ± 0.5; ileum 6.2 ± 0.6; caecum 23.6 ± 4.2; colon 40.2 ± 4.4, p > 0.05 compared to vehicle group).

Given that gene expression changes in rosiglitazone-treated db/db mice were largely confined to the ileum and colon, gene annotation maps were generated using the Reactome pathway database with focus on these two gut segments (Fig. 3D). Consistent with the marked changes in ileal and colonic global gene expression profiles, rosiglitazone-treated db/db mice displayed significant changes in several biological signaling pathways. DEGs were particular associated with Protein localization, Metabolism, and Immune system pathways (Fig. 3D). Perturbations in metabolic pathways were dominated by lipid metabolism-associated genes (Fig. 3E, 4C). While changes in Protein Localization and Lipid Metabolism pathways were most marked in the colon, the ileum showed more significant regulations linked to the Immune system (Figs. 3D, 4D).

Considering the molecular target for rosiglitazone, transcriptome changes in the ileum and colon were probed for PPAR-associated transcriptional pathways, revealing a wide representation of PPAR-associated genes across the Reactome pathway categories (Fig. 4A). Accordingly, several DEGs implicated in peroxisomal proliferation (Ppara) protein import (Cat, Epox2, Pex14, Pex19, Slc27a2) and peroxisomal fatty acid β-oxidation (Abcd3, Acaa1a, Acaa1b, Acox1, Acox2, Crt, ECH1, Ehhadh, Hsd17b4) were upregulated (Fig. 4A, C), indicating stimulation of PPAR-γ following long-term rosiglitazone treatment in diabetic db/db mice. In addition, rosiglitazone upregulated the expression of genes involved in mitochondrial β-oxidation and oxidative phosphorylation (Aca2, Cpt1a2, Cpt2, Slc22a5, Slc25a20). Notably, rosiglitazone stimulated fatty acid metabolism as indicated by regulation of genes involved in intestinal fatty acid absorption/transport (Fabp1, Fabp2, Fabp5, Slc27a1, Slc27a2, Slc27a4), synthesis (Acacb, Acox12) and degradation (Chrm11, Mgl, Pla2g5, Pla2g10, Plb1, Pla2a2) (Fig. 4A, C). Furthermore, cytochrome genes linked to lipid metabolism (Cyp4a10, Cyp2c66, Cyp4b1, Cyp2b6) were significantly upregulated in the colon, but not in the ileum (Fig. 4C). A subset of DEGs were associated with glucose metabolism, including upregulation of genes
Fig. 3. RNA gene expression analysis of db/db gut sections. (A) Total number of differentially expressed genes in the five gut sections compared with vehicle at significance level \((p < 0.05\) after correction for multiple testing). (B) Venn diagram with genes regulated between treatment and vehicle specific to colon, ileum or shared between the two sections. (C) Principal Component Analysis (PCA) of the 500 most variable genes. The points indicate the relationship between samples across gene expression profiles. Gut sections are coloured, and treatment groups shaped. Group means are indicated by a large point. Whilst PC1 separates the small from the large intestine, PC2 clusters the individual gut segments demonstrating tissue-specific gene signatures. (D) Reactome pathways affected by rosiglitazone treatment. Pathways indicated in bold were further investigated (see Figure 4). (E) Reactome metabolism sub-pathways affected by rosiglitazone treatment.
involved in gluconeogenesis (Gpi1, Slc25a10, Slc37a2, Slc25a1) and glycerol biogenesis (Pdk4) in the colon. In addition, rosiglitazone treatment resulted in downregulation of caecal and ileal genes involved in glycolysis (Aldob, Enolb, Hk1) (Fig. 4B). In addition to metabolic pathways, immunomodulatory genes were regulated by rosiglitazone treatment, particularly markers associated with innate immune system responses. This includes genes associated with monocyte/macrophage function (Cd68, C3ar1, Card9, Lys2, Map3k8, Saa1), B-cell (Mme) and T-cell activation (Prkcq), NK cells (Fgfr3) as well as enteric glial cells (Gdnf). Other regulated genes have been associated with antigen processing (Asb11), mucosal defense (Cat, Slpi) and the complement system (C7, Colec10, C1s2, Fcna). In addition, gut tight junction markers were investigated. Compared to vehicle controls, two colonic genes were significantly downregulated (*p < 0.05; **p < 0.01; ***p < 0.001) and one ileal gene upregulated (**p < 0.01) following rosiglitazone treatment. All other tight junction-associated genes (Cdh1, Cdh17, Cgn, Cldnd1, Cldn2, Cldn3, Cldn4, Cldn5, Cldn15, Ctnmb1, F11r, Jam3, Jam1, Marveld2, Ocln, Tjp1, Tjp2, Tjp3) were unaffected by treatment, irrespectively of the gut segment analysed.

4. Discussion

Rosiglitazone is an oral antidiabetic agent of the thiazolidinedione (TZD) class that improves glycaemic control primarily by increasing peripheral insulin sensitivity through selective activation of PPAR-γ particularly by stimulating gene expression programs that increase glucose uptake and improve insulin-stimulated glucose disposal [5,6]. Here, we report that long-term rosiglitazone treatment does not influence the gut microbiome profile in diabetic db/db mice while having profound effects on intestinal genes involved in nutrient metabolism. This could suggest a contributory role of gut-derived PPAR-γ signalling in the metabolic effects of TZDs.

The small intestine plays a central role in nutrient absorption, digestion and immune function, whereas the proximal colon is primarily involved in water absorption and fermentation of dietary fibres [39–41]. This makes it imperative to study local pharmacological effects on the gut microbiota composition, as analysis of the faecal microbiome closely reflects the microbiota profile of the distal colon only [42–44]. The present study profiled the microbiome composition across five different gut segments representing the entire rostro-caudal extension of the intestine in diabetic db/db mice. To avoid sample extraction bias, a dual DNA and mRNA purification kit was employed to enable direct comparison of local gut microbial composition and host gene expression profiles across the rostro-caudal extension of the gut. The simultaneous bacterial DNA-host mRNA isolation procedure enabled paired analysis of local gut microbiome and gut transcriptome signatures in rosiglitazone-treated db/db mice.

Recent studies have demonstrated discrete phylum/genus-level changes in the faecal gut microbiome in chow-fed db/db mice compared to chow-fed C57BL6 mice which are likely driven by hyperphagia [45,46]. Compared to vehicle-dosed db/db mice, rosiglitazone treatment did not influence gut segmental microbiome profiles in db/db mice. TZDs have previously been reported to have no effect on the faecal microbiome composition in DIO mice and rats [41,47], suggesting the intestinal microbiome may not play a contributory role in the metabolic effects of PPAR-γ agonists. On the other hand, the gut microbiota may modulate endogenous intestinal PPAR-γ activity which could have implications for nutrient metabolism. Accordingly, recent studies have demonstrated that PPAR-γ signalling in gut epithelial cells can be induced by short-chain fatty acids, the main metabolites produced by
gut bacterial fermentation of dietary fibres [15,40,48,49]. Although there is increasing evidence that short-chain fatty acids and other microbial metabolites such as 3-indolepropionic acid and secondary bile acids have effects on host physiology, including energy/glucose metabolism, inhibition of microbial dysbiosis and protection of gut barrier function [12,50,51], it remains to be established whether gut PPAR-γ specifically contribute to these effects. The 16S sequencing analysis was limited to determine gut bacterial composition at the family/genus level in db/db mice, and it cannot be excluded that deeper sequencing may reveal discrete compositional changes at species level following rosiglitazone treatment in this type 2 diabetes model. Although the present dosing regimen significantly improved hyperglycemia in db/db mice, we cannot rule out that higher rosiglitazone doses or longer treatment duration could influence gut microbiome composition. As in the clinic, use of relatively high doses of rosiglitazone (≥10 mg/kg/day) is associated with significant weight gain in mice [52,53]. Given that weight gain is strongly correlated with gut microbiome changes [29], it should be considered that higher doses may potentially influence gut microbiome composition related to the adverse, rather than therapeutic, effects of rosiglitazone.

Studies on intestinal transcriptional responses to PPAR-γ agonists, including rosiglitazone, have typically been limited to characterization of pre-selected genes [15,41,54-56]. To obtain further resolution of local gut effects of TZDs, we performed unsupervised analysis of gut segmental transcriptome changes following rosiglitazone treatment. In contrast to the lack of effect on the gut microbiome, rosiglitazone showed a marked effect on the intestinal gene expression profile in db/db mice, being largely localized to the ileum and colon. The significant colonic transcriptome changes were consistent with the colon showing highest expression of PPAR-γ. In the small intestine, ileal gene expression was responsive to rosiglitazone even though all segments of the small intestine displayed up to 10-fold lower PPAR-γ expression compared to the colon. Whether these effects may be explained by more effective PPAR-γ mediated signal transduction or ileal accumulation/uptake of rosiglitazone must await further studies.

PPAR-γ in adipose tissues is the primary target for the blood glucose-lowering effects of TZDs, predominantly through activation of adipocyte lipid flux and adipocyte differentiation whereby fat is sequestered away from insulin-resistant tissues such as skeletal muscle and the liver [57-59]. Also, stimulated adipokine release may play a role in the anti-diabetic effects of TZDs [60]. A large set of regulated intestinal genes in rosiglitazone-treated db/db mice were known PPAR-γ targets associated with gut lipid metabolism [56]. Consistent with PPAR-γ acting as a main gut lipid sensor [10,49], rosiglitazone treatment stimulated the expression of several gene markers of intestinal fatty acid uptake, transport and disposal. This effect was particularly observed in the colon which is consistent with PPAR-γ being abundantly expressed in colonic epithelial cells [13,14,56]. The implications of stimulated colonic PPAR-γ associated lipid metabolic signalling is unclear as the majority of lipid digestion and absorption occurs in the small intestine and only a small proportion of dietary fat reaches the large intestine [39,61]. It should be emphasized that the colon is exposed to lipids derived from undigested dietary fat and to a lesser extent from endogenous secreted lipids and colonocytes shed at the gut epithelial surface [62]. In addition to dietary factors, short-chain fatty acids serve as important energy substrates for colonocytes [63]. It is possible that rosiglitazone also triggered lipid metabolism programs in non-parenchymal gut cell types. Accordingly, macrophages and dendritic cells are abundant in the gut [64,65], show high PPAR-γ receptor expression [66] and PPAR-γ receptors can activate fatty acid β-oxidation and triglyceride clearance in these immune cell subsets [67,68].

Intestinal gene expression profiles in rosiglitazone-treated db/db mice included regulation of ileal and colonic genes associated with carbohydrate metabolism. Although a subset of regulated genes encodes enzymes involved in gluconeogenesis and glycolysis, it should be noted that these enzymes are multifunctional and have diverse roles in e.g. cell migration and immune signaling [69,70]. The functional implications of these discrete changes are therefore unclear, however, may likely reflect local gut adaptive metabolic responses being unrelated to the glycaemic effects of rosiglitazone.

In addition to the prominent metabolic effects, intestinal PPAR-γ signalling controls the activity of several inflammatory response genes in epithelial cells, macrophages, dendritic cells and T-cells which is considered an important molecular mechanism for shaping gut immune responses to bacterial load and dietary immunogens [71,72]. Rosiglitazone has previously been demonstrated to exert intestinal anti-inflammatory effects [26,27]. Inflammatory tissue responses and gut dysbiosis have been demonstrated in obese and diabetic patients [73,74], however, a causal link between intestinal dysfunction and type 2 diabetes remains to be conclusively established. Impaired gut barrier integrity has been suggested to be an important driver of chronic low-grade inflammation in obesity and diabetes [75,76]. Accordingly, db/db mice have been reported to show indices of low-grade systemic inflammation, impaired gut barrier function and intestinal pro-inflammatory activity [45,50,77], which may potentially be linked to disrupted intestinal glucose transport and signaling [78,79]. Our study indicates that gene expression of tight junction components was largely unaffected by rosiglitazone treatment, which could suggest that gut barrier function did not contribute to the glucoregulatory effects of rosiglitazone in db/db mice. It should be noted that gut microbiome-host cross-talk at the level of immune cell signalling is important in both physiological and inflammatory conditions [19,21]. In the present study, oral rosiglitazone treatment altered the expression of immune gene markers, however, did not affect gut bacterial composition throughout the gut in db/db mice. In combination, this argues for gut microbiota-independent immunomodulatory effects of rosiglitazone and suggests a potential therapeutic role for TZDs in metabolic gut inflammatory diseases.

5. Conclusion

Rosiglitazone improves glucose homeostasis without altering the gut microbiome composition in diabetic db/db mice. Rosiglitazone promoted marked changes in local intestinal transcriptome signatures of metabolic reprogramming towards increased intestinal lipid utilization and altered gut immune signalling, which could suggest that rosiglitazone may potentially improve local gut metabolic function associated with diabetes.

Funding

This study was supported by a grant from Innovation Fund Denmark (M.S.M., grant no. 7038-00008B).

Authors contributions statement

Conceived and designed the experiments: R.V.G., J.E., M.S.M, J.J., N. V. and M.M.; performed the experiments: M.S.M and M.C.D; analyzed and interpreted the data: M.S.M., K.R., M.R.M, M.M., J.J. and H.H.H.; wrote the manuscript: M.S.M., M.M., J.J. and H.H.H. All authors have read and approved the final manuscript.

Data availability statement

All data generated or analyzed during this study are included in this published article.

Declaration of Competing Interest

References

[47] M.S.A. Madsen et al.

Biomedicine & Pharmacotherapy 133 (2021) 110966


